Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
GS030
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
25 Oct 2018
Ophthalmology Innovation Summit @ AAO, Chicago (IL)
27 Oct 2018 - 30 Oct 2018
American Academy of Ophthalmology, Chicago (IL)
26 April 2018
GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
27 May 2018 - 30 May 2018
ISCAS 2018, Florence, Italy
16 May 2018 - 19 May 2018
21st Annual Meeting ASGCT, Chicago (IL), US
29 Apr 2018 - 03 May 2018
ARVO Annual Meeting, Honolulu, Hawaï, US
10 January 2018
GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa
16 October 2017
GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy
08 May 2017
GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
31 January 2017
GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa
View previous 9 articles
1
2
3
4
5
6
View next 9 articles
Go back to the page of the page